Background: Sevoflurane is degraded during low-flow anesthesia to fluoromethyl-2,2-difluoro-l-(trifluoromethyl)vinyl ether ("compound A"), which causes renal necrosis in rats but is not known to cause nephrotoxicity in surgical patients. Compound A is metabolized to glutathione S-conjugates and then to cysteine S-conjugates, which are N-acetylated to mercapturic acids (detoxication pathway), or metabolized by renal p-lyase to reactive intermediates (toxification pathway) and excreted as ~,3,3-trifluoro-2-fluoromethoxypropanoic acid. This investigation quantified compound A metabolites in urine after low-flow sevoflurane administration, to assess relative flux v i a these two pathways.
thoxypropanoic acid excretion continued for 3 days in some patients. Total (3-day) mercapturates and fluoromethoxypropanoic acid excretion was 95 f 49 and 294 +. 416 pmol, respectively (1.2 f 0.6 and 3.6 f 5.0 pmoVkg).
Conclusion: Compound A doses during 3.7 MAC-h, low-flow sevoflurane administration in humans are substantially less than the threshold for renal toxicity in rats (200 pmovkg). Compound A metabolites quantification may provide a biomarker for compound A exposure and relative metabolism via toxification and detoxication pathways. Compared with previous investigations, relative metabolic flux (fluoromethoxypropanoic acid/mercapturates) through the toxification pathway was sixfold greater in rats than in humans. Species differences in dose and metabolism may influence compound A renal effects. (Key words: Anesthetic degradation; haloallcene; p-lyase; glutathione; nephrotoxicity.) SEVOFLCJKANE undergoes basecatalyzed degradation in carbon dioxide absorbents to the haloalkene fluoromethyl-2,2dilIuoro-1 -(trifluoromethyl)vinyl ether ("compound A"), which occurs in higher amounts during low-flow anesthesia. Typical of numerous haloalkenes,2,3 compound A causes nephrotoxicity in rats, specifically corticomedullary proximal tubular necrosis, accompanied by proteinuria, glucosuria, and enzym~ria.~.~ The threshold for renal tubular necrosis in rats (250 g) is generally accepted to be 290-340 ppm * h. [5] [6] [7] There are, however, species differences in the threshold for compound A nephrotoxicity. Monkeys showed histologic and biochemical evidence of renal toxicity at 800 ppm -h but not 600 ppm * h.' Swine showed no renal tubular cell necrosis after 612 ppm h, and a threshold for toxicity has not been established. ' In humans, numerous investigations have evaluated renal function after surgical anesthesia with low-flow sevoflurane, in which maximum inspired compound A concentrations averaged 8-24 and 20-32 ppm with soda lime and barium hydroxide lime, respectively, and exposures were as high as 400 ppm * h."-" Using standard clinical (creat- inine clearance, senun creatinine, and BUN) and experimental (proteinuria, glucosuria, and enzymuria) markers of renal functiondl and structural integrity, investigations to date have found no evidence of renal toxicity after administration of low-flow anesthesia,'"-15 although one"' but not another" found mild, transient proteinuria, suggesting altered glomenilar permeability. Like numerous other haloalkenes,'.' compound A undergoes glutathione conjugation, with renal uptake and metabolism of Sconjugates ( fig. 1 ). There are extensive qualitative similarities in compound A metabolism between rats and humans. In rats, compound A undergoes nonenzymatic and glutathione S-transferase catalyzed metabolism to two alkane (diastereomers of S-[ 1,l ,difluoro-2-fluoromethoxy-2-(trifluoromethyl)ethyl]-glutathione) and two alkene ((E) and (0S-L 1-fluoro-2-flluoromethoxy-2-(trifluorornetIiyl)vinyl]~utathione) glutathione conjugates, which undergo cleavage to the corresponding cysteine S-conjugates, 18-20 Cysteine Sconjugates N-acetylation forms the mercapturic acids N-acetyl-S-(1,1,3,3,3-pentafluor~2-fl~ioro-methoxypropy1)icysteine and (0 and (Z)-N-acetyl-S-(lfluoro-2-fluoromethoxy-2-(t~u~romethyl)v~yl~i.-~~steine, which are excreted in rat urine.'8,20,2' These mercapturic acids have also been qualitatively identified in human urine after administration of low-flow sevoflurane," indicating that compound A glutathione-and cysteine Sconjugate formation also occurs in humans. Compound A cysteine Sconjugates are metabolized by rat renal cysteine conjugate plyase in vitro and in vizm to reactive intermediates Iyer et al. reported that 3,3,3-trifluoro-2-fluoromethoxypropanoic acid could decompose to trifluorolactic acid.'* Identification of 3,3,3-tritluoro-2-fluoromethoxypropanoic acid and trifluorolactic acid in urine after low-flow sevoflurane administrationz2 indicated that compound A cysteine Sconjugates can also undergo plyasecatalyzed metabolism in humans.
Compound A and other haloalkene cysteine S-conjugate metabolism by renal P-lyase is considered a toxitication pathway, whereas N-acetylation and mercapturic acid formation is regarded as a detoxication pathwaY.7,'8-25 Although compound A mercapturates and P-lyase-dependent metabolites have been qualitatively identified in human urine, they have not been quantified, and the relative metabolic flux through these toxification and detoxication pathways in humans has not been determined. In addition, interspecies differences in the relative metabolic flux through these pathways may confer differences in susceptibility to compound A nephrotoxicity. Therefore the purpose of this investigation was to provide GC/MS identification of compound A mercapturates, 3,3,3-trifluoro-2-fluoromethoxypropanoic acid, and trifluorolactic acid in human urine, and to quantify metabolite excretion reflecting relative compound A toxification and detoxication in humans undergoing lowflow sevoflurane anesthesia.
Materials and Methods

Clinical Protocol
Twenty-one patients who were American Society of Anesthesiologists physical status 1-111, without history of hepatic or renal disease, and undergoing anesthesia for elective noncardiac and nonaortic surgery with planned duration > 2 h were studied. Patients ( 5 men, 16 women) aged 49 ? 12 yr (range, 30-69 yr) and weighing 76 t 12 kg (range, 52-97) were studied. The investigation was approved by the Institutional Review Board, and all patients provided written informed consent. The anesthetic protocol was designed to maximize compound A formation (fresh barium hydroxide lime, total gas flow rate 1 l/min, and high sevoflurane concentrations, achieved by precluding opioids [except 50 -150
Fg fentanyl for induction], nitrous oxide, and intraoperative neuraxial opioids and local anesthetics). End-tidal anesthetic concentrations were monitored continuously (Capnomac, Datex Medical Instrumentation, Tewksbury, MA). Respiratory gas samples were obtained using gastight syringes, from the inspiratory (FJ and expiratory (FJ limbs of the anesthesia circuit adjacent to the respective valves, and from a catheter positioned coaxially in the endotracheal tube with the tip protruding just beyond the tube orifice after ventilation was held for 30 s (alveolar samples, FA). Samples were obtained after intubation, 5, 10, 15, 30, 60, 90, and 120 min after the start of low-flow anesthesia, hourly thereafter, and at the end of low-flow anesthesia. Urine was collected in 24-h intervals for 72 h after anesthesia. The volume was measured, and an aliquot was frozen at -80°C for later analysis. Additional details regarding the experimental protocol, and results of renal function evaluations in a multicenter superset of these patients, have been published previously. I5 Data in this investigation represent additional evaluations performed at the time of the original investigation, and subsequent laboratory studies, on the University of Washington cohort from the previous investigation.
Ana(yticu1 Methods
Compound A concentrations in respiratory gas samples were determined by gas chromatography with flame ionization detection, as described previously. l5 Urine concentrations of N-acetyl-S(1,1,3,3,3-pentafluorc-2-(fluoromethoxy)propyl)-~qsteine, N-acetyl-S-(l-fluoro-2-(fluoromethoxy)2-(trifluoromethyl)-vinyl)-~qsteine, 3,3,3- trifluoro-2(fluoromethoxy)propanoic acid, and trifluorolactic acid were determined by GUMS as described previously.2" Briefly, the internal standards N-acetyl-S(2,2di-fluro-vinyl)-I,-cysteine (I .25 pg) or dichloroacetic acid (1 50 ng) were added to urine (0.1-1 ml) that was acidified and extracted with diethyl ether. Samples were derivatized with diazomethane or diphenyldiazomethane for mercapturic acid or fluoropropionic acid analysis, respectively, and analyzed by GC/MS. Analyses were performed on a Hewlett-Packard 5890 Series I1 GC-5972 mass selective detector, using a DB17 column (30 m x 0.32 nun x 0.5 p) a & W Scientific, Folsom, CA). The injector and detector temperatures were 250°C and 300°C, respectively, and the column head pressure was 5 psi for all assays. For mercap turates analysis, the oven was at 35°C for 5 min, increased time. To permit comparison with the previously published data,15 the 5-, I@, and 15-min samples were not used for this calculation. The dose of compound A actually administered was taken as compound A uptake, calculated as described previously for sevoflurane and other anesthetics." Uptake rate was calcdated as where V,, was the total pulmonary uptake rate (L compound A vapor/min), V, was the minute ventilation (I/min), and F, and F, were the inspired and mixed expired compound A concentrations, respectively, determined at each measurement interval. F, was calculated according to where fA and f,, represent the fraction of alveolar and dead space ventilation, respectively. Values for fA and fi, during mechanical ventilation were taken as 0.5 each.2x
Mixed-expired gas samples are conventionally obtained by placing a mixing box in the expiratory limb of the anesthesia circuit. Preliminary studies showed that sevoflurane concentrations in mixed expired samples obtained distal to a 3-1 mixing box were not substantially different than those measured at the end of the circuit adjacent to the expiratory valve without the box (not shown); thus, the mixing box was not subsequently used to obtain mixed-expired compound A samples. V,, was therefore also calculated using F, for F, , which provided an upper bound (more conservative estimate) of VI,. Values for total pulmonary compound A uptake (l/min) were converted to mol/min by application of the general gas equation." The sum of the products of pulmonary compound A uptake rate and exposure time for each interval gave the total dose in moles.
Results are expressed as the mean 2 SD. Correlations were analyzed by linear regression analysis. Statistical significance was assigned at P < 0.05.
Results
Compound A Concentrations
Compound A was readily detected at the first sampling time, 5 min after the start of low-flow anesthesia. Mean concentrations are shown in figure 2A . Concentrations in most patients plateaued after approximately 30 min (shown previously' 5 ) . They continued to increase in three patients, two of whom underwent laparoscopic procedures with CO, insufflation19 and who also re- ceived much higher sevoflurane concentrations (3.0%, 3.1%, and 2.6%) compared with all others (mean, 1.9%), which influenced the mean values. Expired and alveolar compound A concentrations were significantly correlated (slope = 0.77, r2 = 0.75, P < 0.001, data not shown), although there was greater variability in the latter measurement ( fig. 2A) , possibly reflecting the fact that mechanical ventilation, but not fresh gas flow, was interrupted during alveolar sampling. Compound A uptake was approximated from the F,:F, ratio ( fig. 2B) although the equilibrium ratio was only 0.64 at 2 and 3 h.
Similar results were obtained using the more conventional F,:F, ratio, although variability was greater because of the greater variability in FA (not shown).
Compound A exposure and estimated dose are provided in table 1. Exposure, measured as the inspired AUC (AUCinbp), was 78 i 58 ppm h (range, 10-223).
Total dose, estimated from the pulmonary uptake rate, and conventionally calculated using FA and F, to determine F, , was 0.23 i 0.22 mmol. Uptake was also calculated using F, as the value for F, (0.39 i 0.35 mmol; 4.8 ? 4.0 pmol/kg). This method avoids potential sampling confounders, makes no assumptions about the proportions of alveolar and dead space ventilation,'* does not consider any compound A adsorption by the anesthesia circuit,'" and provides a more conservative (higher) estimate for dose. There was a significant correlation (r2 = 0.84, P < 0.001) between this dose and compound A exposure measured as AUCi,,,, (fig. 3A) or as AUCinsp.exp (r2 = 0.78, P < 0.001, data not shown). A similar correlation was also observed (r' = 0.84) using the lower estimate for compound A dose and AUCinbP (not shown). The higher estimate for compound A dose (0.39 ? 0.35 mmol) is used in the remainder of this report. There was also a significant correlation (r2 = 0.76, P < 0.001) between compound A dose and sevoflurane exposure (MAC-h; fig. 3B ). 5A, 16.2 min) , based on selected-ion monitoring, although concentrations were low (0 -l . l pg/ml), highly variable, and insufficient to obtain full scan mass spectra of the excreted compound. Identification, therefore, was based on selected-ion monitoring of diagnostic ions, as described previously. '
Compound A Metabolites Excretion
Daily excretion of mercapturic acids and P-lyase-de- capturic acids were readily detected for 2 days postoperatively in all subjects, and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid was detected in all patients on day 1, and in approximately half of the patients by day 3. In contrast, trifluorolactic acid concentrations were above the limit of quantification in only five subjects on day 1 and in only two subjects on day 2. Cumulative 3-day metabolite excretion is shown in figure 6 . This investigation was designed, in part, to provide a more thorough characterization of compound A disposition than conventionally obtained in clinical studies, in which only inspired concentrations are measured, and usually beginning 0.5-2 h after initiation of low-flow ane~thesia."'-"'~~'-~~ Some of these more recent investigations have ~alculated compound A exposure (AIJC,,,,) using the trapezoidal nile from the origin to the first measured time. We detected compound A 5 min after the start of low-flow anesthesia, and at concentrations greater than would have been predicted by extrapolating linearly from time zero to the first 0.5-2 h measurement. One other investigation also detected compound A immediately after the onset of low-flow anesthesia." These results show that many previous investigations have somewhat underestimated actual compound A exposure, with the underestimate greater for those measuring compound A beginning at 2 h.34335 Compound A uptake, estimated from the FEEI ratio, was rapid. The FE/FI ratio of 0.64 observed presently is similar to that previously described by Frink et al. 1032933 It is also consistent with the FA& ratio of 0.8 reported to be achieved after 1-2 h, in which end-tidal gas samples were used to estimate alveolar compound A concentrations.'" The rapid increase in F,(,JF, ratio is consistent with the low solubility of compound A (bloodgas partition coefficient of 0.31);37 however, the equilibrium value is lower than the solubility would predict. As identified earlier,36 this may relate to compound A reactivity with blood and plasma constituents," most likely protein thiols,'x21' and possibly also reactivity with tissue thiols. lC),. j8 The dose of compound A taken up can be compared with exposure to compound A and to sevoflurane. Compound A exposure (measured as AUC,,,,) was an excellent predictor of compound A dose (measured from inspired and expired compound A concentrations and minute ventilation). Low-flow sevoflurane exposure (end-tidal MAC-h) was also an excellent predictor of the compound A dose (approximately 0.1 mmol compound A per MAC-h low-flow [l l/min] sevoflurane). These relationships can be used to estimate compound A doses in other investigations in which it is not measured directly.
Low-flow sevoflurane in this investigation (3.7 2 2.0 MAC-h) resulted in a compound A dose of 0.39 t 0.35 mmol. Previously, a similar sevoflurane exposure (3.7 ? 0.3 MAC-h) resulted in a sevoflurane dose of 88.8 ? 28.8 r n m~l .~' Assuming that the same sevoflurane exposure in the present investigation resulted in similar sevoflurane uptake, the compound A dose was approximately 1/200 that of sevoflurane. This finding is consistent with several investigations showing that inspired compound A concentrations are approximately 1/500 -1/1,000 those of sevoflurane,'2'31 and with the solubility and F,(,JF, ratio for compound A.
Compound A doses administered during low-flow anesthesia in humans can be compared with those causing nephrotoxicity in rats. Although animal investigations using inhalation exposure do not permit assessment of the actual compound A dose admini~tered,~-' doses are known when intraperitoneal injection is used.25 The nephrotoxic threshold in rats was 200 pmol/kg intraperitoneal compound A," which produced histologic and biochemical alterations similar to those elicited by the inhaled threshold of 290-340 ppm -h.5-7 The com- luoro-2-fluoromethoxypropanoic acid has been reported to be unstable, degrading to trifluorolactic acid.14 Quantification of this degradation product in uivo might be important, because it would also represent cysteine Sconjugates metabolism by plyase. Trifluorolactic acid was rarely observed, however, and never accounted for more than a small fraction of the 3,3,3-trifluoru2-fluoromethoxypro panoic acid excreted in human urine. Assay sensitivity does not appear to explain this result, as recovery averaged 95% and 0 . 1~d m l was readily detectable. Trifluorolactic acid excretion in human urine after low-flow sevoflurane was identified previously.** Excretion was not quantified, but qLralitatively appeared small relative to that of the mercaphirates and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid.'* Thus, although 3,3,3-trifluoro-2-fluoromethoxyprcpanoic acid decomposition to trifluorolactic acid readily occurred in vitro,l4 this finding does not appear quantitatively significant in humans in uivo.
Relative cysteine S-conjugates metabolism by p-lyase versus N-acetylation can be assessed by comparing cumulative excretion of p-lyase-dependent fluoroacids (3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid plus trifluorolactic acid) and mercapturic acids (alkane plus alkene). The ratio of fluoroacids to mercapturates was approximately 1.5:l after 1 day (determined to permit comparison with animal data, see below) and 3: 1 after 3 days.
Although haloalkene metabolism and toxification by the glutathione-dependent P-lyase pathway has been amply demonstrated in animals, relatively few haloalkenes have been shown to undergo metabolism by this route in humans, and even less quantitative information is available. Urinary excretion of the mercapturic acid metabolites of tr"h1oroethene'"'' and tetrachloroethene",4' was recently shown in humans receiving occupational or deliberate exposure, demonstrating the biosynthesis of glutathione-and cysteine S-conjugates. Urinary excretion of chloroacetic acid after tri~hloroethene~' and dichloroacetic acid after tetrachl~roethene~' showed that P-lyase-dependent cysteine S-conjugates metabolism can also occur in humans. Compound A appears to be the first fluoroalkene shown to undergo metabolism in humans by the glutathione-dependent p-lyase pathway, the first fluoroalkene in which metabolism by N-acetykdtion and renal P-lyase has been quantified and may be an excellent probe to explore the toxicologic significance of these pathways in humans.
Limited comparisons of quantitative metabolism of compound A and other haloalkenes in humans are available. After occupational exposure to 200-400 ppm -h tetrachloroethene, mercapturic acid excretion in spot urine samples was 0.010 -0.015 nmol/mg creatinine."
In volunteers exposed to 60, 120, or 240 ppm * h tetrachloroethene, cumulative 35-h mercapturic acid excretion was 45 i 12, 142 +-14, and 211 t 46 nmol, or approximately 0.045, 0.14, and 0.21 nmol/mg creatinine (assuming 1 g/day creatinine excretion), and appeared essentially complete after 35 h.'' After 240,480, and 960 ppm * h volunteer exposure to trichloroethene, cumulative 48-h excretion of mercapturic acids was 2 5 0 2 40, 370 2 30, and 430 i 10 nmol, or approximately 0.25, 0.37, and 0.43 nmol/mg creatinine.'"' After trichloroethene intoxication, mercapturic acid excretion on days 1-3 was 0.26, 0.42, and 1.25 nmol/mg creatinine.*' In the present investigation after 78 +-58 ppm * h compound A, mercapturates excretion was 59 2 34, 3.5 i 8 . 2 , and 0 nmol/mg creatinine on days 1-3. Thus mercapturates of compound A were excreted as fast or faster than those of other haloalkenes. Quantitatively, excretion of compound A mercapturates (nmol/kg) also appeared greater than that of other haloalkenes, likely reflecting the fact that these other haloalkenes also undergo considerable cytochrome P450-mediated metabolism,'"4' whereas compound A undergoes comparatively less P450-mediated metabolism.58 We find only one investigation that measured urinary excretion of P-lyase-dependent haloacid metabolites after haloalkene exposure in humans. dichloroacetic acid after 60, 120, or 240 ppm -h tetrac h l~r o e t h e n e .~~
The present report appears to be the first to quantify p-lyase-dependent haloacid metabolite excretion after haloalkene exposure in humans.
Interspecies Comparisons
For numerous haloalkenes and their cysteine S-conjugates,2,' including compound metabolism by renal P-lyase to reactive intermediates is considered to confer bioactivation and toxification, whereas N-acetylation is considered to be a detoxication pathway, although other pathways of compound A cysteine S-conjugates metabolism have also been suggested to cause
Relative metabolic flux through toxification and detoxication pathways is considered, in part, to determine nephrotoxicity. After inhalation of identical tetrachloroethene concentrations in rats and humans, dichloroacetic acid excretion (reflecting p-lyase-dependent toxification) was orders of magnitude higher in rats than in humans. 43 Furthermore, in rats, cumulative dichloroacetic acid excretion was 30-to 80-fold greater than that of the mercapturic acid N-acetyl-S-(trichloroviny1)-I.-cysteine (reflecting detoxication), suggesting considerably greater cysteine S-conjugate metabolism by p-lyase than by N-a~etylation.~~ In contrast, in humans, p-lyase-dependent metabolism of tetrachloroethene was not observed. 43 For tetrachloroethene, greater Sconjugate formation in rats compared with humans, and their more intensive metabolism by p-lyase in rats compared with humans, were interpreted to suggest that reactive intermediate formation in the kidney was greater in rats than in humans after similar exposure conditions, that humans are less sensitive to the nephrotoxic effects of tetrachloroethene, and that risk assessments based on rat data would overestimate human risks. 43 For compound A, similar species differences in metabolism are apparent. Urinary excretion of mercapturic acids and p-lyase-derived fluoroacid metabolites, representing detoxication and toxification, are compared in rats and humans ( fig. 7) . Rats underwent exposure to 138 ppm * h inhaled compound A,' the dose which was closest to that in the present patients, and urine metabolite concentrations were determined using the same assays as used herein." Rat urine was collected for 24 h, thus 24-h data from the present human investigation are shown for comparison. Fluoroacid excretion (reflecting P-lyase-dependent metabolism) was 15-fold higher in rats than in humans. The ratio of fluoroacids to mercapturates was sixfold greater in rats" than in humans (1.7). 
, 2 J
These in vivo results are consistent with previous in vitro data showing that p-lyase-catalyzed metabolism of compound A cysteine-S-conjugates was 8-to 30-times greater in rat compared with human kidneys. 23 In summary, this investigation quantified human exposure and dose of compound A, as well as compound A S-conjugates metabolism by N-acetylation (detoxication) and P-lyase (toxification), and compared them to previous results in rats, which appear more susceptible to compound A nephrotoxicity. Humans, compared with rats, receive markedly lower doses of compound A and metabolize a lower fraction by renal 0-lyase than by N-acetylation. These species differences may influence compound A renal'effects.
